Bliss GVS Pharma Limited (NSE:BLISSGVS)
India · Delayed Price · Currency is INR | Market Cap | 46.13B +247.0% |
| Revenue (ttm) | 8.68B +7.2% |
| Net Income | 1.09B +83.0% |
| EPS | 10.19 +81.2% |
| Shares Out | n/a |
| PE Ratio | 42.28 |
| Forward PE | n/a |
| Dividend | 1.00 (0.23%) |
| Ex-Dividend Date | Feb 18, 2026 |
| Volume | 1,122,249 |
| Open | 427.00 |
| Previous Close | 424.65 |
| Day's Range | 424.00 - 440.00 |
| 52-Week Range | 118.00 - 462.80 |
| Beta | 0.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About Bliss GVS Pharma
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provide... [Read more]
Financial Performance
In fiscal year 2025, Bliss GVS Pharma's revenue was 8.10 billion, an increase of 5.13% compared to the previous year's 7.70 billion. Earnings were 842.99 million, an increase of 11.72%.
Financial StatementsNews
Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma
Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited at a price of ₹299 per share.…
Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan
Bliss GVS Pharma Limited is the target of an open offer from Anupam Rasayan India Limited, which seeks to acquire up to 2,77,26,848 fully paid-up equity shares. This represents 26%…
Bliss GVS Pharma achieves WHO-GMP compliance for manufacturing facility
Bliss GVS Pharma has announced that its manufacturing facility in Vevoor Village, Palghar, Maharashtra, has been confirmed to comply with the Good Manufacturing Practices (GMP) standards set by the Wo...
Why are Bliss GVS Pharma shares rallying over 15% today? Explained
Shares of Bliss GVS Pharma surged sharply in early trade on Tuesday, extending their strong momentum for the second straight session after Anupam Rasayan announced plans to acquire a substantial…
Bliss GVS Pharma shares jump 7% after Anupam Rasayan announces ₹1,369 crore stake acquisition deal
Bliss GVS Pharma shares were in sharp focus on Monday morning, rising around 7% at 9:30 am after Anupam Rasayan announced a plan to acquire a substantial stake in the…
Anupam Rasayan India acquires up to 48.2% stake in Bliss GVS Pharma
Anupam Rasayan India Ltd. has announced a significant acquisition, entering into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes ...
Anupam Rasayan India to acquire up to 48.2% stake in Bliss GVS Pharma
Anupam Rasayan India Ltd. has announced its entry into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes an open offer…
Anupam Rasayan to acquire up to 74.20% stake in Bliss GVS Pharma for Rs 1,369 crore
Anupam Rasayan India has announced its board's approval for acquiring up to 74.20% of Bliss GVS Pharma's equity shares. The acquisition will be executed through a share purchase agreement and…
Anupam Rasayan to acquire 74.20% stake in Bliss GVS Pharma for Rs 1,369 crore
Anupam Rasayan India has announced its intention to acquire a significant stake in Bliss GVS Pharma, a move designed to bolster its presence in the pharmaceutical sector. The acquisition involves…
Bliss GVS Pharma Quarterly report: Q4 2026
Bliss GVS Pharma has published its Q4 2026 quarterly earnings report on May 12, 2026.
Bliss GVS Pharma Quarterly report: Q3 2026
Bliss GVS Pharma has published its Q3 2026 quarterly earnings report on February 10, 2026.
Bliss GVS Pharma shares fall over 15% today as EBITDA drops 20% and margins shrink to 13%
Friday, November 7: Shares of Bliss GVS Pharma Ltd declined sharply by 15.8% to Rs 127.94 in early trade after...
Bliss GVS Pharma Q2 results: Net profit up 2.5% to Rs 25.69 crore; EBITDA down 20%, margin contracts to 13%
Friday, November 7: Bliss GVS Pharma Ltd reported a modest performance for the quarter ended September 30, 2025, with revenue...
Bliss GVS Pharma Quarterly report: Q2 2026
Bliss GVS Pharma has published its Q2 2026 quarterly earnings report on November 6, 2025.
Bliss GVS Pharma Quarterly report: Q1 2026
Bliss GVS Pharma has published its Q1 2026 quarterly earnings report on July 30, 2025.
Bliss GVS Pharma Annual report: Q4 2025
Bliss GVS Pharma has published its Q4 2025 annual report on May 2, 2025.
Bliss GVS Pharma Quarterly report: Q4 2025
Bliss GVS Pharma has published its Q4 2025 quarterly earnings report on May 2, 2025.
Bliss GVS Clarifies USFDA ANDA Approval for Mesalamine Suppositories
Bliss GVS Pharma Limited has issued an official clarification confirming that its marketing and distribution partner in the United States, Rising Pharma Holdings Inc., has received final approval from...
Bliss GVS Pharma Quarterly report: Q3 2025
Bliss GVS Pharma has published its Q3 2025 quarterly earnings report on January 28, 2025.
Bliss GVS Pharma shares surge 4% after company receives GMP Compliance certification for its manufacturing facilities in Palghar
Bliss GVS Pharma’s stock rose 4% in morning trade after the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This certification was granted after a rigorous inspection by R...
Bliss GVS Pharma receives GMP Compliance certification for manufacturing facilities in Palghar, Maharashtra
Bliss GVS Pharma Limited has recently informed exchanges that the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This recognition comes after a comprehensive inspection c...